Prosol and Clinisol
Guidance for plan sponsors on potential billing errors associated with two amino acid preparations, Prosol (20% amino acid injection) and Clinisol, and to encourage plan sponsors to review billing patterns, and evaluate and consider taking measures to ensure the appropriate billing of these two products under the Medicare Advantage and Prescription Drug programs.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: May 09, 2019
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.